Sees FY26 Adjusted EBITDA Higher than FY25, CapEx Below $10M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Sees FY26 adjusted EBITDA higher than FY25 and CapEx of less than $10M.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGI
Wall Street analysts forecast OGI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.140
Low
2.36
Averages
2.64
High
2.91
Current: 1.140
Low
2.36
Averages
2.64
High
2.91
About OGI
Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organigram Reports Disappointing Q2 Results, Stock Drops 15%
- Revenue Decline: Organigram reported net revenue of C$59.8 million ($43.6 million) for Q2 FY2026, reflecting a ~9% year-over-year decline primarily due to lower vape and infused pre-roll sales, marking its first topline contraction since Q2 FY2024 and missing the ~8% growth forecasted by analysts.
- Gross Margin Drop: The company's gross margin fell by 200 basis points to 31% compared to the prior year, driven by changes in product mix and increased product returns, indicating pressure on profitability amid a competitive market environment.
- Widening Net Loss: Organigram swung to a net loss of C$0.9 million compared to a net income of C$42.5 million in the same period last year, primarily due to weaker fair value gains on derivative liabilities and preferred shares, alongside declining revenue and gross margin, highlighting a deterioration in financial health.
- Revised Full-Year Outlook: The company updated its full-year net revenue guidance to over C$350 million from more than C$300 million previously, reflecting revised revenue recognition criteria related to the Sanity Group acquisition in April, indicating cautious optimism for future performance.
See More
Organigram Reports Q2 Net Loss Amid Revenue Decline
- Financial Performance Decline: Organigram reported a net loss of $0.9 million in Q2 2026, a stark contrast to a net income of $42.5 million in Q2 Fiscal 2025, indicating a significant drop in profitability that may undermine investor confidence.
- Revenue Downtrend: The company posted total revenue of $93.3 million, a 9.2% year-over-year decline, although it exceeded market expectations by $42.82 million, the ongoing revenue decrease could pressure future growth prospects.
- Adjusted EBITDA Plummets: Adjusted EBITDA fell to $0.9 million, an 82% decrease compared to $4.9 million in Q2 Fiscal 2025, highlighting significant challenges in cost management and profitability.
- Stable International Revenue: International revenue remained flat at $6.1 million year-over-year, showing resilience in a declining overall revenue context, which may indicate stable market demand despite broader challenges.
See More
Organigram Announces Q2 Fiscal 2026 Earnings Report Date
- Earnings Report Schedule: Organigram Global Inc. will report its Q2 fiscal 2026 earnings on May 12, 2026, before market open, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 8:00 AM Eastern Time on the same day to discuss the earnings results, ensuring investors receive timely information for informed decision-making.
- Webcast Access: Investors can register via the provided link to join the conference call, with confirmation emails sent containing dial-in details, enhancing engagement and participation with stakeholders.
- Company Background: Organigram is Canada's leading cannabis company focused on producing high-quality cannabis products and expanding its market presence in the US and Canada through acquisitions, demonstrating strategic positioning in a rapidly evolving industry.
See More
Cannabis Edibles Market Experiences Rapid Growth
- Market Size Projections: The global cannabis edibles market is expected to reach approximately $7.1 billion by 2025 and climb to around $16.6 billion by 2030, indicating a strong growth trajectory driven by consumer demand for cleaner, more discreet consumption methods.
- Successful International Export: Herbal Dispatch has successfully completed its first export of medical cannabis gummies to Australia, generating approximately $350,000 in revenue, marking a significant milestone in the company's international growth strategy and reinforcing its position as a trusted supplier in the global medical cannabis market.
- Product Diversification Strategy: Herbal Dispatch is actively expanding its gummies and edibles offerings domestically under the Chomp brand, responding to strong consumer demand across both medical and recreational channels, highlighting the company's focus on convenient, dose-controlled formats to drive long-term growth.
- Emerging Investment Opportunities: With potential U.S. federal reform and the ongoing expansion of medical programs globally, the cannabis edibles market is positioned at the intersection of several powerful trends, likely capturing a larger market share and driving revenue diversification in high-growth categories.
See More
Organigram Completes Acquisition of Sanity Group
- Acquisition Completed: Organigram successfully acquired Sanity Group for €107.3 million, comprising €78 million in cash and €29.3 million in shares, marking a significant step in its European market expansion strategy.
- Financing Arrangement: The acquisition was accompanied by a private placement financing with BAT, raising €40.3 million (approximately C$65.2 million), which provided essential funding support for the acquisition and enhanced the company's financial flexibility.
- Future Earnings Potential: The acquisition agreement includes earnout provisions of up to €113.8 million based on Sanity Group's financial performance over the next 12 months, reflecting Organigram's confidence in its long-term growth potential.
- New Board Member: Following the acquisition, Max Konrad Narr was appointed to Organigram's board of directors, expected to provide crucial support for the company's strategic decision-making and market integration.
See More
Organigram Shareholders Approve Acquisition of Sanity Group
- Shareholder Resolution: At the March 30, 2026, shareholders' meeting, Organigram's shareholders overwhelmingly approved the resolution to acquire Sanity Group with 93% of votes, marking a significant step in the company's global cannabis market expansion.
- Significant Financial Impact: The acquisition is expected to enhance Organigram's revenue and profitability, with Sanity Group achieving positive EBITDA in 2025, further solidifying Organigram's leadership in the rapidly growing German medical cannabis market.
- Strategic Integration Benefits: The acquisition will provide Organigram with a vertically integrated European hub, enhancing its commercial, operational, medical, and regulatory expertise across the value chain, facilitating future market expansion.
- Innovative Product Development: The combination of both teams is expected to drive the development of next-generation cannabis innovations, leveraging science-backed intellectual property to further extend Organigram's brand influence in global markets.
See More
Organigram Reports Disappointing Q2 Results, Stock Drops 15%
- Revenue Decline: Organigram reported net revenue of C$59.8 million ($43.6 million) for Q2 FY2026, reflecting a ~9% year-over-year decline primarily due to lower vape and infused pre-roll sales, marking its first topline contraction since Q2 FY2024 and missing the ~8% growth forecasted by analysts.
- Gross Margin Drop: The company's gross margin fell by 200 basis points to 31% compared to the prior year, driven by changes in product mix and increased product returns, indicating pressure on profitability amid a competitive market environment.
- Widening Net Loss: Organigram swung to a net loss of C$0.9 million compared to a net income of C$42.5 million in the same period last year, primarily due to weaker fair value gains on derivative liabilities and preferred shares, alongside declining revenue and gross margin, highlighting a deterioration in financial health.
- Revised Full-Year Outlook: The company updated its full-year net revenue guidance to over C$350 million from more than C$300 million previously, reflecting revised revenue recognition criteria related to the Sanity Group acquisition in April, indicating cautious optimism for future performance.
See More
Organigram Reports Q2 Net Loss Amid Revenue Decline
- Financial Performance Decline: Organigram reported a net loss of $0.9 million in Q2 2026, a stark contrast to a net income of $42.5 million in Q2 Fiscal 2025, indicating a significant drop in profitability that may undermine investor confidence.
- Revenue Downtrend: The company posted total revenue of $93.3 million, a 9.2% year-over-year decline, although it exceeded market expectations by $42.82 million, the ongoing revenue decrease could pressure future growth prospects.
- Adjusted EBITDA Plummets: Adjusted EBITDA fell to $0.9 million, an 82% decrease compared to $4.9 million in Q2 Fiscal 2025, highlighting significant challenges in cost management and profitability.
- Stable International Revenue: International revenue remained flat at $6.1 million year-over-year, showing resilience in a declining overall revenue context, which may indicate stable market demand despite broader challenges.
See More
Organigram Announces Q2 Fiscal 2026 Earnings Report Date
- Earnings Report Schedule: Organigram Global Inc. will report its Q2 fiscal 2026 earnings on May 12, 2026, before market open, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 8:00 AM Eastern Time on the same day to discuss the earnings results, ensuring investors receive timely information for informed decision-making.
- Webcast Access: Investors can register via the provided link to join the conference call, with confirmation emails sent containing dial-in details, enhancing engagement and participation with stakeholders.
- Company Background: Organigram is Canada's leading cannabis company focused on producing high-quality cannabis products and expanding its market presence in the US and Canada through acquisitions, demonstrating strategic positioning in a rapidly evolving industry.
See More
Cannabis Edibles Market Experiences Rapid Growth
- Market Size Projections: The global cannabis edibles market is expected to reach approximately $7.1 billion by 2025 and climb to around $16.6 billion by 2030, indicating a strong growth trajectory driven by consumer demand for cleaner, more discreet consumption methods.
- Successful International Export: Herbal Dispatch has successfully completed its first export of medical cannabis gummies to Australia, generating approximately $350,000 in revenue, marking a significant milestone in the company's international growth strategy and reinforcing its position as a trusted supplier in the global medical cannabis market.
- Product Diversification Strategy: Herbal Dispatch is actively expanding its gummies and edibles offerings domestically under the Chomp brand, responding to strong consumer demand across both medical and recreational channels, highlighting the company's focus on convenient, dose-controlled formats to drive long-term growth.
- Emerging Investment Opportunities: With potential U.S. federal reform and the ongoing expansion of medical programs globally, the cannabis edibles market is positioned at the intersection of several powerful trends, likely capturing a larger market share and driving revenue diversification in high-growth categories.
See More
Organigram Completes Acquisition of Sanity Group
- Acquisition Completed: Organigram successfully acquired Sanity Group for €107.3 million, comprising €78 million in cash and €29.3 million in shares, marking a significant step in its European market expansion strategy.
- Financing Arrangement: The acquisition was accompanied by a private placement financing with BAT, raising €40.3 million (approximately C$65.2 million), which provided essential funding support for the acquisition and enhanced the company's financial flexibility.
- Future Earnings Potential: The acquisition agreement includes earnout provisions of up to €113.8 million based on Sanity Group's financial performance over the next 12 months, reflecting Organigram's confidence in its long-term growth potential.
- New Board Member: Following the acquisition, Max Konrad Narr was appointed to Organigram's board of directors, expected to provide crucial support for the company's strategic decision-making and market integration.
See More
Organigram Shareholders Approve Acquisition of Sanity Group
- Shareholder Resolution: At the March 30, 2026, shareholders' meeting, Organigram's shareholders overwhelmingly approved the resolution to acquire Sanity Group with 93% of votes, marking a significant step in the company's global cannabis market expansion.
- Significant Financial Impact: The acquisition is expected to enhance Organigram's revenue and profitability, with Sanity Group achieving positive EBITDA in 2025, further solidifying Organigram's leadership in the rapidly growing German medical cannabis market.
- Strategic Integration Benefits: The acquisition will provide Organigram with a vertically integrated European hub, enhancing its commercial, operational, medical, and regulatory expertise across the value chain, facilitating future market expansion.
- Innovative Product Development: The combination of both teams is expected to drive the development of next-generation cannabis innovations, leveraging science-backed intellectual property to further extend Organigram's brand influence in global markets.
See More
